Efficacy News and Research

RSS

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

Selenium supplements and heart disease risk: an interview with Dr Saverio Stranges, University of Warwick

Selenium is a micronutrient which has antioxidant properties by means of selenoproteins which play many important functions in the body. They actually are contained in many different foods. The amount of selenium we get from diet is closely linked to the amount of selenium in the soil.

21 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

Dabigatran decreases risk of recurrent venous thromboembolism

New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Dog owners concerned about daily living with osteoarthritis

Carprofen for the treatment of dogs with osteoarthiritis significantly improves owner-assessed chronic pain as well as lameness compared with placebo, show US study results.

20 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Study reveals rare look into success of substance abuse treatment programs for African-Americans

New research out of the University of Cincinnati reveals a relatively rare look into the success of substance abuse treatment programs for African-Americans. Researchers report that self-motivation could be an important consideration into deciding on the most effective treatment strategy.

20 Feb 2013

BioCryst fourth quarter revenues decrease to $4.1 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2012.

19 Feb 2013

Antimuscarinic effective for overactive bladder in elderly

The antimuscarinic drug fesoterodine seems to be an effective and well-tolerated treatment for elderly individuals with an overactive bladder, including those older than 75 years, show findings from a clinical trial.

19 Feb 2013

Insights into HIV-1 virion makeup could improve gene therapy

A discovery about how the HIV-1 virion packages genomic RNA may help researchers to improve the efficacy of gene therapy.

18 Feb 2013

Clot evacuation reduces perihematomal edema in hemorrhagic stroke

Minimally invasive surgery combined with recombinant tissue-type plasminogen activator significantly reduces perihematomal edema in patients with intracerebral hemorrhage.

18 Feb 2013

Positive results from Neurim’s Piromelatine phase II study on insomnia

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia.

18 Feb 2013

Study paves way for new prosthetics that connect directly to the nervous system

For an amputee, replacing a missing limb with a functional prosthetic can alleviate physical or emotional distress and mean a return of vocational ability or cosmetics. Studies show, however, that up to 50 percent of hand amputees still do not use their prosthesis regularly due to less than ideal functionality, appearance, and controllability. But Silvestro Micera, of the -cole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland, is paving the way for new, smart prosthetics that connect directly to the nervous system.

18 Feb 2013

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).

16 Feb 2013

Patients with untreated depression are poorly protected by shingles vaccination

Results from a new study published in Clinical Infectious Diseases suggest a link between untreated depression in older adults and decreased effectiveness of the herpes zoster, or shingles, vaccine.

16 Feb 2013

Stroke specialists offer guidance on questions about thrombolytic therapy use

One of the most challenging issues in stroke care involves the use of clot-busting drugs such as tPA. When given quickly enough and to the right patient, such drugs can minimize stroke damage by dissolving blood clots that cause most strokes. But these blood-thinning drugs also increase the risk of brain hemorrhages and other complications.

16 Feb 2013

Efficacy News and Research

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

Selenium supplements and heart disease risk: an interview with Dr Saverio Stranges, University of Warwick

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Dabigatran decreases risk of recurrent venous thromboembolism

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Dog owners concerned about daily living with osteoarthritis

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Study reveals rare look into success of substance abuse treatment programs for African-Americans

BioCryst fourth quarter revenues decrease to $4.1 million

Antimuscarinic effective for overactive bladder in elderly

Insights into HIV-1 virion makeup could improve gene therapy

Clot evacuation reduces perihematomal edema in hemorrhagic stroke

Positive results from Neurim’s Piromelatine phase II study on insomnia

Study paves way for new prosthetics that connect directly to the nervous system

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

Patients with untreated depression are poorly protected by shingles vaccination

Stroke specialists offer guidance on questions about thrombolytic therapy use

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Depression reduces efficacy of shingles vaccine

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News